02.09.23
A new ingredient by Sabinsa is proven to support healthy blood sugar and chlolesterol levels.
In a recently published, 90-day, multicentric randomized open label trial, Sabinsa’s Amla ingredient Saberry was found to provide blood sugar support benefits.
In a recently published, 90-day, multicentric randomized open label trial, Sabinsa’s Amla ingredient Saberry was found to provide blood sugar support benefits.
Saberry, a patented ingredient, is the only Indian Gooseberry extract standardized with beta glucogallin, a Gallotannin compound, which holds the key to health benefits obtained from Indian gooseberry. Saberry is a self-affirmed GRAS ingredient that has been consumed as a dietary supplement for more than a decade. It has an excellent taste profile and water soluble.
In the study, Saberry was shown to significantly improve the key parameters of blood sugar levels, both fasting and post prandial, and lipid levels (LDL, VLDL and total cholesterol) in subjects with hyperglycemia and BMI ranging from 27-35. The study design used three arms with a total 126 subjects for comparing two dosages of Saberry supplementation (1g and 2g) with standard treatment group (metformin 500mg).
Both the dosages of Saberry showed improvement in glucose and lipid metabolism in a dose dependent manner with 2g showing 21.8% lowering of fasting blood sugar levels compared to 14.6% with a 1g dosage. While 1g dose compared favorably with metformin results, 2g dose surpassed them. Similar trends were noted with both dose regimen for total cholesterol, LDL, VLDL, and triglyceride levels.
Read the paper here.